Skip to main content
Fig. 9 | Stem Cell Research & Therapy

Fig. 9

From: Additional benefit of induced pluripotent stem cell-derived mesenchymal stem cell therapy on sepsis syndrome-associated acute kidney injury in rat treated with antibiotic

Fig. 9

Protein expressions of inflammation in kidney by day 5 after SS-AKIR procedure. A Protein expression of tumor necrosis factor (TNF)-α. B Protein expression of matrix metalloproteinase (MMP)-9. C Protein expression of interleukin (IL)-6. n = 6 for each group. * indicates p value  < 0.05; ** indicates p value  < 0.01; *** indicates p value  < 0.001; **** indicates p value  < 0.0001. G1 = (sham-operated control); G2 = sepsis syndrome (SS) + acute kidney ischemia–reperfusion (AKIR); G3 (SS + AKIR + ciprofloxacin administered at 3 h after SS-AKIR induction); G4 [SS + AKIR + iPS-MSCs by intravenous injection at 3 h, after SS-AKIR (i.e., defined as early treatment)]; G5 [SS + AKIR + iPS-MSCs by intravenous injection at 18 h after SS-AKIR (i.e., defined as late treatment) after SS-AKIR induction]; G6 [SS + AKIR + ciprofloxacin and iPS-MSCs at 3 h after SS-AKIR induction]. iPS-MSCs = induced pluripotent stem cells-derived mesenchymal stem cells

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512